RE: Large volume 25% up30 Jan 2026 09:38
Peers trade x 10 or x 20 annual revs
PYC juat x 1
[ ] Key market drivers
* model informed discovery/bio stats help
> costs $2.5bln and 10-15yrs to get drug to market and less than 5% success rate - PYC modelling drastically cuts this and using MMID/BS can
1) save $100-500mln
2) increase to 20-30% success at Phase II
3) 30-50% fewer patients
[ ] Key growth/CAGR markets which PYC operate
MMID 18% CAGR with market set to be $13bln
Bio Statistics 24% CAGR $40bln market
Regulatory authorities across the world require robust biometrics practices to approve new drugs. Biometrics typically incorporates three main areas:
1. Biostatistics: Supporting the design of clinical studies and analysis of resulting data
2. Statistical Programming: Use of programming language to process, analyse and visualise clinical data
3. Data Management: Setup and oversight of the collection, entry, and validation of clinical trial data
Personalised medicine 7.5% CAGR and largest market is North America ( partner DoseMeRx based there)
General overviews
Total Income at 3yr high and bolstered by moving into new therapeutic areas such as immunology and cardiovascular